Therapeutic Classification: opioid analgesics
Pharmacologic Classification: opioid agonists analgesics
High Alert
Absorption: Well absorbed after IM and SUBQ administration. IV administration results in complete bioavailability.
Distribution: Unknown.
Half-Life: Children (18 yr): 0.9 hr; Adults: 3.55 hr.
Contraindicated in:
Use Cautiously in:
CV: hypertension, orthostatic hypotension, palpitations
Derm: ↑sweating, clammy feeling
EENT: blurred vision, diplopia, miosis (high doses)
Endo: adrenal insufficiency
GI: dry mouth, nausea, vomiting, constipation, ileus
GU: urinary urgency
Neuro: dizziness, headache, sedation, confusion, dysphoria, euphoria, floating feeling, hallucinations, unusual dreams
Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA)
Misc: allodynia, opioid-induced hyperalgesia, physical dependence, psychological dependence, tolerance
Drug-drug:
Drug-Natural Products:
Analgesia
Supplement to Balanced Anesthesia
Lab Test Considerations:
Toxicity and Overdose:
Do not confuse nalbuphine with naloxone.
FDA strongly encourages health care professionals to complete a REMS-compliant education program that includes all the elements of the FDA Education Blueprint for Health Care Providers Involved in the Management or Support of Patients with Pain, available at www.fda.gov/OpioidAnalgesicREMSBlueprint. Information on programs can be found at 1-800-503-0784 or www.opioidanalgesicrems.com.
IV Administration: